- Home
- Advocacy
- Latest News and Practice Data
- Patient Advocates, Physicians, Others Support FDA LDT Rule
Several organizations representing patients, physicians, and other nonprofit groups filed court briefs supporting the Food and Drug Administration (FDA) regulation on laboratory-developed tests (LDTs) on November 4. The groups urged the court to deny motions by the American Clinical Laboratory Association (ACLA) and Association for Molecular Pathology (AMP) to vacate the FDA final LDT rule.
Read the three amicus briefs filed by:
- Public Citizen, American Cancer Society Cancer Action Network, Association for Clinical Oncology (ASCO), Friends of Cancer Research, National Brain Tumor Society, and Ovarian Cancer Research Alliance.
- The Center for Science in the Public Interest, a nonprofit consumer advocacy organization.
- Democracy Forward representing practicing physicians and pharmaceutical and medical device policy analysts.
The CAP has filed its own amicus brief urging the court to stop the FDA LDT rule from being implemented. Read the CAP’s amicus brief to the court cases ACLA et al. v. FDA, and AMP et al. v. FDA, US District Court Eastern District of Texas.